Marex president sells 15,271 shares in plan

Marex Group Ltd’s president reported pre-planned open-market sales totaling 15,271 ordinary shares under a Rule 10b5-1 trading plan.

Available on EDGAR 09/16/2026 - 04:05 PM EDT Accepted by SEC EDGAR 09/16/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Marex Group Ltd (MRX) reported that its President, Simon Van Den Born, sold a total of 15,271 Ordinary Shares on September 14, 2026 in open-market transactions under a Rule 10b5-1 trading plan adopted on June 12, 2026. The reported holdings associated with this filing include deferred bonus plan awards that are settled in ordinary shares upon vesting.

Insider Trade Summary 10b5-1

Net Seller: 15,271 shares

Net Sell 2 txns

Insider Van Den Born Simon

Role President

Sold 15,271 shs ($1.08M)

Share of Position Sold 1.0%

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	12,616	$70.7689	$893K
Sale	Ordinary Shares F1, F3, F4	2,655	$71.3585	$189K

Holdings After Transaction: Ordinary Shares — 1,470,348 shares (Direct)

Holdings Before and After: Ordinary Shares, 1,485,619 to 1,470,348 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (4)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on June 12, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $70.23 to $71.225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $71.23 to $71.6 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The number of ordinary shares reported herein includes 272,659 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Key Figures

Total shares sold: 15,271 shares First sale size: 12,616 shares First sale price range: $70.23–$71.225 per share +3 more

6 metrics

Total shares sold 15,271 shares Ordinary Shares sold by the president on September 14, 2026

First sale size 12,616 shares Ordinary Shares sold at weighted average price of $70.7689

First sale price range $70.23–$71.225 per share Price range for 12,616-share sale on September 14, 2026

Second sale size 2,655 shares Ordinary Shares sold at weighted average price of $71.3585

Second sale price range $71.23–$71.60 per share Price range for 2,655-share sale on September 14, 2026

Deferred bonus plan awards underlying shares 272,659 shares Contingent rights to receive one ordinary share each upon vesting

Key Terms

Rule 10b5-1 plan, weighted average price, deferred bonus plan awards

3 terms

Rule 10b5-1 plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

deferred bonus plan awards financial

"includes 272,659 shares underlying deferred bonus plan awards previously granted"

Deferred bonus plan awards are payments promised to employees or executives that are earned now but paid out later, often only if certain performance goals are met or the employee remains with the company. For investors, they matter because they influence management’s incentives and company expenses over time—like a delayed paycheck that encourages someone to stay and meet targets—and can affect future cash needs, reported compensation costs, and potential share dilution.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Marex Group Ltd (MRX) shares did Simon Van Den Born sell in this Form 4?

Simon Van Den Born reported selling a total of 15,271 Ordinary Shares of Marex Group Ltd on September 14, 2026, across two open-market transactions reported in this Form 4.

At what prices were the MRX shares sold by the president on September 14, 2026?

The president sold 12,616 shares at a weighted average price of $70.7689 (range $70.23–$71.225) and 2,655 shares at a weighted average price of $71.3585 (range $71.23–$71.60).

Were the MRX share sales by Simon Van Den Born made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 plan entered into by Simon Van Den Born on June 12, 2026, and the plan-status affirmation box is checked.

What is Simon Van Den Born’s role at Marex Group Ltd (MRX) in this Form 4?

In this Form 4, Simon Van Den Born is identified as an officer of Marex Group Ltd, holding the title of President, and he is the reporting person for the disclosed transactions.

Do the reported MRX holdings include deferred bonus plan awards?

Yes. A footnote explains the reported ordinary share holdings include 272,659 shares underlying deferred bonus plan awards, each representing a contingent right to receive one ordinary share upon vesting and settlement.

Were any derivative securities reported in this Marex Group Ltd (MRX) Form 4?

No. The filing’s derivative summary is empty, and all reported transactions involve Ordinary Shares as non-derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Den Born Simon

(Last) (First) (Middle)

C/O MAREX GROUP LIMITED, 155 BISHOPSGATE

(Street)

LONDON EC2M 3TQ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Marex Group Ltd [ MRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/14/2026		S(1)		12,616	D	$70.7689(2)	1,473,003	D
Ordinary Shares	09/14/2026		S(1)		2,655	D	$71.3585(3)	1,470,348(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on June 12, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $70.23 to $71.225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $71.23 to $71.6 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The number of ordinary shares reported herein includes 272,659 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

	/s/ Scott Linsley as Attorney-in-Fact, for Simon van den Born	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)